Clinical trials: Benign Hyperplasia of Prostate
Benign Prostatic Hyperplasia
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients with benign prostatic hyperplasia.
- Trial name
- NCT04947631
- Testing
- DKF-313, Dutasteride, Tadalafil
- Where
- South Korea
- Volunteers
- 667 people
- Sponsor
- Dongkook Pharmaceutical Co., Ltd.
Acute Urinary Retention, Benign Prostatic Hyperplasia
Prostatic Urethral Lift in Subject With Acute Urinary Retention
Assess feasibility and safety of the Prostatic Urethra Lift (PUL) procedure in patients with acute urinary retention secondary to benign prostatic hyperplasia (BPH).
- Trial name
- NCT03194737
- Testing
- UroLift System Procedure
- Where
- 6 sites in United Kingdom
- Volunteers
- 101 people
- Sponsor
- NeoTract, Inc.
Prostatic Hyperplasia
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
Patients who are currently symptomatic and have been diagnosed with BPH by a physician may qualify for this 20-week study. Patients must not be diabetic, must not have prostate cancer and must not have had any surgery to repair…
- Trial name
- NCT00044226
- Testing
- ML-04A
- Where
- 14 sites in United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Milkhaus Laboratory
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Urology, Urinary Bladder, Overactive
Ambulatory Long Length URodynamics Evaluation
A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.
- Conditions
- Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics
- Trial name
- ALLURE (NCT07425015)
- Testing
- Glean Urodynamics System
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Bright Uro
Lower Urinary Tract Symptoms, Overactive Bladder
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder…
- Conditions
- Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT02715024
- Testing
- Tamsulosin, Solifenacin
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Taiwan, Inc.
Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic…
- Trial name
- NCT07146386
- Testing
- H077 sustained-release tablet, Silodosin capsules Control Group
- Where
- 66 sites in China
- Volunteers
- 728 people
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
Urinary Calculi, Benign Prostatic Hyperplasia
Flexiva Pulse Registry
To obtain post-market safety and efficacy data for FlexivaTM Pulse High Power Single-Use Laser Fibers during lithotripsy and soft tissue procedure of holmium laser enucleation of the prostate (HoLEP).
- Trial name
- NCT05027971
- Testing
- Flexiva Pulse High Power Single-Use Laser Fibers
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: 1.
- Trial name
- NCT00077012
- Testing
- QLT0074, Photodynamic therapy
- Where
- 7 sites in United States, Canada
- Sponsor
- QLT Inc.
Benign Prostatic Hyperplasia
Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH
Primary: To assess the safety of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH.
- Trial name
- NCT00347061
- Testing
- afuzosin
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil
A randomized, open label, single dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety/tolerability of YY-201 in comparison to Dutasteride and Tadalafil administered in healthy male volunteers
- Trial name
- NCT03240939
- Testing
- Dutasteride 0.5 mg, Tadalafil 5 mg, YY-201
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yuyu Pharma, Inc.
Prostatic Hyperplasia, Benign
Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia
To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia
- Trial name
- NICCOLO (NCT07270432)
- Testing
- Product DNN.65.21.005, Combodart®
- Volunteers
- 218 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Uterine Fibroid, Arteriovenous Malformations
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
- Conditions
- Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
- Trial name
- RAVI Registry (NCT04272216)
- Testing
- Treatment with HydroPearl via radial access
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Terumo Medical Corporation
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Embosphere® PROstate Post Market Study
Prostatic artery embolization with Embosphere Microspheres is a relatively new procedure. The goal of this post market study is to evaluate long-term safety and effectiveness in a 'real world' setting.
- Trial name
- PROstate (NCT03527589)
- Testing
- Prostate artery embolization
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 499 people
- Sponsor
- Merit Medical Systems, Inc.
Benign Prostatic Hyperplasia
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
The purpose of this study is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) for prostatic artery embolization (PAE) using Embosphere…
- Trial name
- NCT01789840
- Testing
- Embosphere Microspheres, TURP
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Merit Medical Systems, Inc.
Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. (BENIPRO)
The clinical trial to evaluate the fixed-dose combination (N0728), with the aim of providing the Brazilian market with an alternative, potentially effective, safe and convenient therapeutic approach for the treatment of Lower…
- Trial name
- BENIPRO (NCT06546735)
- Testing
- N0728, Vesomni®
- Where
- Brazil
- Volunteers
- 816 people
- Sponsor
- Eurofarma Laboratorios S.A.
Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and effectiveness of using Irreversible Electroporation (IRE) for the treatment of symptomatic benign prostatic hyperplasia (BPH).
- Trial name
- RELIEF (NCT07640776)
- Testing
- Irreversible Electroporation
- Volunteers
- 40 people
- Sponsor
- Angiodynamics, Inc.
Benign Prostatic Hyperplasia
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT00894517
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia (BPH)
PERmixon® in LUTS Evaluation Study (PERLES)
The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using Tamsulosine LP 0.4 mg as a reference treatment.
- Trial name
- PERLES (NCT02121613)
- Testing
- Permixon® 160 mg, Tamsulosine LP
- Where
- 58 sites in Czechia, France and 3 more
- Volunteers
- 833 people
- Sponsor
- Pierre Fabre Medicament
Benign Prostatic Hyperplasia
A Study of Tadalafil in Benign Prostatic Hyperplasia
The purpose of this study is to investigate the pharmacokinetics of tadalafil in Japanese and non-Japanese men with Benign Prostatic Hyperplasia (BPH). The safety of tadalafil will also be studied.
- Trial name
- NCT01183650
- Testing
- Tadalafil
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company